^
Association details:
Biomarker:ATM mutation
Cancer:Prostate Cancer
Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

KEYNOTE-199: Pembrolizumab (pembro) for docetaxel-refractory metastatic castration-resistant prostate cancer (mCRPC).

Published date:
05/16/2018
Excerpt:
Cohorts 1 (C1) and 2 (C2) enrolled patients (pts) with RECIST-measurable PD-L1+ and PD-L1– disease, respectively….The response rate was numerically higher in pts with somatic BRCA1/2 or ATM mutations (12%)….Pembro shows antitumor activity and disease control with acceptable safety in pts with docetaxel-refractory mCRPC, regardless of PD-L1 status...
DOI:
10.1200/JCO.2018.36.15_suppl.5007
Trial ID: